Answers are grounded in this paper and cite their sources.
Introduction: Population-based estimates of myocarditis hospitalisation rates in children in the post-COVID era are lacking. Our study objective was to evaluate paediatric myocarditis rates, outcomes, and complications over the last 15 years, including the post-pandemic period in United States. Methods: We analysed the 2009–2022 Kids Inpatient Database data and used a weighted sample to estimate national hospitalisation rates. We included children <18 years with diagnoses of myocarditis using Health Care Cost and Utilization Project codes. Results: Weighted national myocarditis hospitalisations for the respective years were 716 (2009), 747 (2012), 833 (2016), 846 (2019), and 1416 (2022), which corresponded to an incidence per 100,000 children of 0.96, 1.01, 1.13, 1.16, and 1.93, respectively. The incidence in 2022 after excluding COVID-19-related admissions was 1.3/100,000 ( n = 951). Myocarditis showed a bimodal distribution with age categories of 0–4 and 15–17, comprising of 66% hospitalisations. Mortality rate was 7.4% (335/4558) with a significant decreasing trend over the years (10.2% in 2009 and 5.9% in 2022). Length of stay also decreased from a median of 8 days in 2009 to 6 days in 2022. Arrhythmia was the most common complication (18.6%). Extra-corporeal membrane oxygenation was utilised in 9.2% and ventricular assist device in 3%, with a decreasing trend from 2009 to 2022. Conclusions: Overall hospitalisation rates for myocarditis have increased over the last 15 years, with a significant increase in the post-pandemic era. There has been improvement in the mortality rate and a decrease in length of stay. Almost 1/3 of 2022 admissions were related to COVID-19.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: